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Abstract
Background: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms
from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has
been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms.
Case presentation: Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete
bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms
in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life.
Conclusions: Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis.
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Background
Systemic mastocytosis (SM) is a very rare clonal myelopro-
liferative neoplasm (MPN) [1]. The hallmarks of disease
are mast cell (MC) degranulation and organ infiltration by
multifocal clusters of abnormal mast cells, including bone
marrow. Aggressive systemic mastocytosis (ASM) presents
with symptoms related to organ infiltration by mast cells,
including dermatologic, hematologic, gastrointestinal, and
skeletal manifestations [2]. Mast cell degranulation leads to
various cytokine release, producing pruritus, flushing,
dyspepsia, hypotension, and even shock [2]. The workup of
SM includes testing for mutations that play a role in patho-
genesis and treatment implications. Many of the molecular
defects associated with SM involve activating mutations in
the gene encoding the c-kit receptor, the most common of
which is KIT mutation D816V [3, 4]. D816V, N8221
mis-sense mutation, and Val559lle juxtamembrane-type
mutation are all KIT mutations that render imatinib
resistance in mast cells [5]. There are some mutations not
associated with the activation loop of KIT, such as K5091
mutation and Phe522Cys KIT mutation, in which imatinib
can be effective [5]. Cytoreductive agents have been used
in attempts to control ASM, but treatment remains
challenging and mostly palliative. Clinical trials are
investigating treatment with KIT D816V inhibitors in
relapsed or refractory disease. Cytokine release symptoms
are typically treated with histamine receptor antagonists
and glucocorticoids, but can remain debilitating despite
systemic disease control [6].
Ruxolitinib, a potent inhibitor of JAK1 and JAK2, has
been shown in the literature to reduce symptoms related
to proinflammatory cytokine release in hematologic
diseases. The COMFORT-I and COMFORT-II trials
using Ruxolitinib showed a significant decrease in
disease related symptoms in patients with myelofibrosis
[7, 8]. The RESPONSE trial showed similar results with
significant symptom improvement in patients with poly-
cythemia vera using Ruxolitinib [9]. Here we present a case
using Ruxolitinib for disabling constitutional symptoms
despite complete bone marrow response in a patient with
aggressive SM. Myeloproliferative Neoplasm Symptom
Assessment Forms (MPN-SAF), the European Organisation
for Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire–Core 30 Version 3.0 (QLQ-C30), Brief
Fatigue Inventory (BFI), and Patient Global Impression
of Change (PGIC) were used to assess symptom
response [7–10].* Correspondence: ayacoub@kumc.eduDivision of Hematology and Oncology, Univerity of Kansas Medical Center,
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of Life Group granted permission to use the EORTC
QLQ. HIPPA approval was obtained and approved by
KUMC IRB.
Case presentation
A 30-year-old woman was diagnosed with aggressive
systemic mastocytosis at age 9 after battling with cutane-
ous and gastrointestinal symptoms for 4 years. At age
24, she suffered significant progression of her symptoms
with disabling fatigue, flushing, and chronic bone pain
requiring high doses of narcotic analgesia. Bone marrow
biopsy at that time showed 50 % involvement with mast
cells and her tryptase level was 101 ng/mL. KIT muta-
tion analysis showed a rare K509I mutation that is sensi-
tive to imatinib [11]. She was started on imatinib
100 mg daily and achieved complete bone marrow
response and normalization of tryptase level. Despite
disease control, patient continued to suffer from signifi-
cant constitutional symptoms.
Subsequent bone marrow biopsy continued to showed
normocellular marrow with no abnormal mast cells.
There was an increase in reticulin fibrosis that was not
previously reported. Jak-2 mutation was negative and
cytogenetics were normal.
Imatinib was continued, but Ruxolitinib was started in
attempt to control symptoms. Ruxolitinib was initiated at
5 mg twice daily and titrated up every 4 weeks over a 24-
week period based on symptoms response and tolerance.
Patient was monitored closely for toxicity or adverse ef-
fects from the addition of Ruxolitinib. Weight, EKG, and
labs including CBC, CMP, amylase, lipase, and tryptase
were collected at baseline and monitored weekly.
Labs and clinical data were recorded with each
Ruxolitinib dose adjustment and results are depicted
in Table 1. Only mild anemia was seen with increasing
doses of Ruxolitinib that reversed once dose was de-
creased. No additional cytopenias were noted. Liver
function, amylase, and lipase remained at baseline. Tryp-
tase remained stable. No EKG changes were seen. Weight
gain was witnessed over the 24-week period.
Symptoms and quality of life were assessed every
4 weeks by EORTC QLQ-C30 (Fig. 1a and b), BFI
(Fig. 2), MPN-SAF (Fig. 3), and PGIC. Patient reported
significant improvement in quality of life due to
symptom reduction. Narcotic requirement was reduced
from Methadone 30 mg daily to 15 mg daily. Flushing re-
solved and cutaneous manifestations markedly improved
(Fig. 4a and b).
Conclusions
Systemic mastocytosis is associated with constitutional
symptoms from mast cell mediated cytokine release that
occurs chronically and episodically. Ruxolitinib is a Jak1/
Jak2 inhibitor that blocks signal transduction for many
cytokine receptors, leading to its effectiveness in patients
with myeloproliferative neoplasms (MPNs).
In the COMFORT-I trial, patients with myelofibrosis
were treated with Ruxolitinib and had significant im-
provement in the total symptom score using the modi-
fied Myelofibrosis Symptom Assessment Form (MFSAF).
MFSAF scores for abdominal pain, pain under the ribs
on the left side, and early satiety, which were all
improved. The PGIC and patient-reported outcomes also
illustrated symptom improvement. The COMFORT-2
trial also evaluated the use of Ruxolitinib in myelofi-
brosis patients. Symptoms and quality of life in this
trial were assessed by the EORTC QLQ-C30 and
Functional Assessment of Cancer Therapy-Lymphoma
scale (FACT-Lym). This study showed improvements in
quality of life and functioning in the patients receiving
Ruxolitinib. Significant reductions were seen in fatigue,
weight loss, dyspnea, insomnia, and pain [7, 8]. The RE-
SPONSE trial randomized patients with polycythemia vera
who were refractory or intolerant to hydroxyurea to
receive Ruxolitinib versus standard therapy. Patient-
reported symptoms were assessed in this trial using the
Table 1 Patient characteristics
Baseline Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
Hemoglobin 12 11.7 11.3 10.5 10.9 11.4 11.6
Platelet count 188 246 277 297 314 296 250
WBC 6.3 6.8 6.9 7.3 7.4 8.0 8.3
Creatinine 0.85 0.88 0.89 0.92 1.02 1.16 1.03
ALT/AST Normal Normal Normal Normal Normal Normal Normal
Amylase/Lipase Normal Normal Normal Normal Normal Normal Normal
EKG Normal Normal Normal Normal Normal Normal Normal
Weight (Kg) 77.9 78.4 80.5 83.7 85.2 85.6 84.6
Tryptase 10.2 NA 10.8 9.6 NA 9.5 9.1
Ruxolitinib dose 5 mg BID 10 mg BID 20 mg BID 15 mg BID 10 mg BID 10 mg BID 5 mg BID
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Myeloproliferative Neoplasm Symptom Assessment Form
(MPN-SAF) diary, EORTC QLQ-C30, Pruritus Symptom
Impact Scale, and PGIC. Fourteen disease related symp-
toms were evaluated by the MPN-SAF and resulted as a
total symptom score. Ruxolitinib led to significant symp-
tom improvement in the polycythemia patients, as well.
[9] A single case in the literature reports on a patient with
KIT-mediated systemic mastocytosis associated with
myelofibrosis treated with Ruxolitinib. This patient also
experienced significant improvement in symptoms and
reduction in splenomegaly [12].
Given the remarkable results and quality of life im-
provement seen in the aforementioned trials when using
Ruxolitinib in the treatment of MPNs, Ruxolitinib was
trialed in our patient in attempts to alleviate the debili-
tating constitutional symptoms of systemic mastocytosis.
EORTC QLQ-C30, BFI, MPN-SAF, and PGIC were the
tools used to assess symptom improvement and
improvement in quality of life in our patient [13]. As
evident in the QLQ-C30 functional scales graph (Fig. 1a),
our patient had improvement in all functional scales and
improvement in quality of life and global health status
with the use of Ruxolitinib. The QLQ-C30 combined
symptoms score (Fig. 1b) decreased dramatically over
the 24 weeks on Ruxolitinib, representing the decrease
in symptomatology experienced by our patient. The BFI
assessment was used on our patient, as fatigue was one
of her most debilitating symptoms. Baseline BFI score of
5.8 was decreased to 2.5 on Ruxolitinib, denoting an
improvement in fatigue (Fig. 2). The MPN-SAF was used
to assess improvement in symptom burden in our
patient. Symptoms evaluated by the MPN-SAF assess-
ment include concentration, early satiety, inactivity,
night sweats, itching, bone pain, abdominal discomfort,
weight loss, and fever. Baseline MPN-SAF total symp-
tom score (TSS) for our patient was near 70 (designated
as severe if ≥ 70) and was reduced to 12 by week 24 on
Ruxolitinib (Fig. 3). It is noteworthy to mention that
higher doses of Ruxolitinib (week 8–12) caused the
MPN-SAF TSS to elevate to the 30–40 range, but this
was still a significant improvement from baseline. As
Ruxolinitib was dose reduced due to worsening anemia
in weeks 16–24, the MPN-SAF TSS did decrease pro-
portionately. PGIC was the last assessment tool used to
monitor symptoms and improvement in quality of life in
our patient. Patient responses range from very much im-
proved to very much worse on this assessment. Our pa-
tient’s response for the PGIC was “much improvement” by
week 24 on Ruxolitinib therapy.
In addition to monitoring for symptom improvement,
adverse events in the setting of Ruxolitinib were
evaluated. Weight gain was reported in other trials
using Ruxolitinib and was also seen in our patient.
No significant adverse events were noted.
Fig. 2 Brief fatigue inventory
Fig. 3 MPN-SAF
Fig. 1 QLQ-C30 Functional scales (a) and combined symptoms
score (b)
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Dose escalations were slow and monitored closely since
Ruxolitinib was being added to imatinib in our patient.
There were no detected toxicities observed in this novel
combination of active agents. The combination of ima-
tinib and Ruxolitinib has been published in the literature
[14] and no serious toxicity has been demonstrated.
Ruxolitinib is a promising and active agent, especially
in terms of symptom improvement and improved quality
of life in a variety of patient subsets. Regardless of the
underlying disease process, it appears that diseases with
proinflammatory and cytokine release mechanisms are
obtaining benefit with the addition of Ruxolitinib. In pa-
tients’ with systemic mastocytosis with difficult to control
symptoms, Ruxolitinib may be a therapeutic consideration.
Controlled prospective clinical trials evaluating the role of
Ruxolitinib in systemic mastocytosis, post-SM myelofibro-
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Fig. 4 Skin rash prior to therapy with Ruxolitinib (a) and 24 weeks post therapy (b)
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